New Tools for Studying Epigenetic Processes Will Aid Drug Developers
By LabMedica International staff writers Posted on 12 Apr 2011 |
Dedicated new products designed to aid investigators studying epigenetic processes or striving to develop drugs for epigenetic targets are now becoming commercially available.
Epigenetics is the study of changes in gene activity that are driven by chemical and enzymatic modifications of the DNA and proteins in chromosomes. Development of tools to study epigenetic processes has been a major project undertaken by PerkinElmer, Inc. (Waltham, MA, USA).
"The development of novel therapies aimed at epigenetic drug targets has intensified over the last several years. PerkinElmer is excited to be in the forefront of this research by introducing a wide range of screening reagents that focus on assay selectivity, sensitivity and speed, factors which researchers indicate are critical requirements,” said Dr. Martina Bielefeld-Sévigny, vice president and general manager of the drug discovery and research reagent solutions group at PerkinElmer.
PerkinElmer's screening assays for epigenetics based on its proprietary homogeneous assay platforms, LANCE Ultra detection assays for peptide substrates and AlphaLISA detection assays for both peptides and full-length proteins. Both platforms lack washing steps and are nonradioactive, antibody-based technologies that offer a unique combination of specificity, sensitivity, dynamic range, and throughput.
PerkinElmer's epigenetic and post-translational screening tools now cover nine different histone markers as well as the p53 tumor suppressor, with more than 15 validated enzyme assays to aid researchers developing novel drug compounds directed against several epigenetic enzymes, such as histone methyltransferases (HMTs), demethylases (HDMs), acetyltransferases (HATs) and deacetylases (HDACs).
Related Links:
PerkinElmer
Epigenetics is the study of changes in gene activity that are driven by chemical and enzymatic modifications of the DNA and proteins in chromosomes. Development of tools to study epigenetic processes has been a major project undertaken by PerkinElmer, Inc. (Waltham, MA, USA).
"The development of novel therapies aimed at epigenetic drug targets has intensified over the last several years. PerkinElmer is excited to be in the forefront of this research by introducing a wide range of screening reagents that focus on assay selectivity, sensitivity and speed, factors which researchers indicate are critical requirements,” said Dr. Martina Bielefeld-Sévigny, vice president and general manager of the drug discovery and research reagent solutions group at PerkinElmer.
PerkinElmer's screening assays for epigenetics based on its proprietary homogeneous assay platforms, LANCE Ultra detection assays for peptide substrates and AlphaLISA detection assays for both peptides and full-length proteins. Both platforms lack washing steps and are nonradioactive, antibody-based technologies that offer a unique combination of specificity, sensitivity, dynamic range, and throughput.
PerkinElmer's epigenetic and post-translational screening tools now cover nine different histone markers as well as the p53 tumor suppressor, with more than 15 validated enzyme assays to aid researchers developing novel drug compounds directed against several epigenetic enzymes, such as histone methyltransferases (HMTs), demethylases (HDMs), acetyltransferases (HATs) and deacetylases (HDACs).
Related Links:
PerkinElmer
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples